China Healthcare Select

Zhejiang Sunshine Mandi Pharmaceutical has submitted a new drug application for its 5% minoxidil foam specifically for female patients with androgenetic alopecia. The filing follows a rigorous Phase 3 clinical trial involving 296 women after an initial indication extension was rejected in 2024. Although the active ingredient concentration remains 5%, the female formulation requires only once-daily application. Sunshine Mandi's foam product, which boasts reduced scalp irritation and superior follicular drug accumulation, generated over CNY 300 million in its first year. The regulatory outcome will set a significant precedent for gender-differentiated indications in China's topical hair-loss treatment market.

Shenzhen Institute of Advanced Biomedical Robot Co., Ltd. (Abrobo) has completed a Series A+ financing round worth tens of millions of RMB, led by PU HE CAPITAL, with strategic follow-on investment from Shenzhen Longgang Financial Investment Holding Co., Ltd. The proceeds will support the commercialization of its vascular interventional surgical robots, expansion of clinical indications, R&D and regulatory registration of intelligent automated and remote surgical systems, and talent recruitment. Founded in 2020, Abrobo focuses on master-slave robotic arm technology to address clinical needs in pan-vascular intervention. The financing is expected to accelerate product deployment and market expansion, supporting the commercialization of its vascular interventional robots amid intensifying global competition.

Walvax Biotechnology Co., Ltd. (300142.SZ) has officially launched a Phase I clinical trial for its lyophilized varicella-zoster virus mRNA vaccine, a potential first-in-class mRNA-based shingles prevention therapy globally. Developed through collaboration with Fudan University and Shanghai Rnacure Biopharma Co., Ltd., the vaccine utilizes Walvax's proprietary mRNA platform technology and features a lyophilized formulation that offers advantages in storage and distribution. The early-stage study will evaluate the safety, tolerability, and immunogenicity of the vaccine candidate in human subjects. With no mRNA-based herpes zoster vaccines currently approved worldwide, this initiative positions Walvax at the forefront of next-generation shingles vaccine development, addressing significant global demand for effective prevention among older adults and immunocompromised individuals.

Balance Medical's new transcatheter pulmonary valve (TPVR) system has received NMPA approval, marking China's second domestically produced TPVR product. It addresses the critical need of approximately 300,000 complex congenital heart disease patients who face repeated open-chest surgeries due to pulmonary valve regurgitation. While existing TPVR devices only accommodate 20-30% of patients with suitable anatomy, Balance Medical introduces an innovative 'reshape first, then implant' technique. This 'all-comer' approach successfully treats complex pulmonary artery deformities, achieving a 100% surgical success rate and an 87.2% 36-month adverse event-free rate in clinical trials, paving the way for comprehensive, lifelong valve management for complex congenital heart disease patients.

Huawei Hengyuan (Beijing) Biomedical Technology Co., Ltd., a Tsinghua University spinoff, has completed regulatory filing under China’s State Council Decree No. 818 for a clinical study of its human induced Sertoli-like cell (hiSC) therapy for rheumatoid arthritis (RA). Registered as MR-N-45-2026-000116, the study is sponsored by Huawei Hengyuan and led by the First Affiliated Hospital of Guangxi Medical University, with participation from Handan Central Hospital. It is Guangxi’s first filing under the new framework effective May 1, 2026, and the 16th nationally. Derived from human fibroblasts using NR5A1 and GATA4 transcription factors, hiSCs have immunomodulatory properties. The study will assess the safety, tolerability, and efficacy of a single intra-articular injection in RA patients with persistent synovial inflammation despite systemic treatment.

Jiangsu Hengrui Pharmaceuticals, China's largest drugmaker by market value, announced on Oct. 13 that its novel injectable candidate SHR-3201 for Alzheimer's disease has received approval from the National Medical Products Administration (NMPA) to commence human clinical trials. Developed by Hengrui's subsidiary Beijing Shengdi Pharmaceutical, the first-in-class formulation aims to clear disease-related brain biomarkers to slow cognitive decline. The company has invested approximately 48.8 million yuan ($6.8 million) in the project. SHR-3201 marks Hengrui's second Alzheimer's drug candidate, complementing its earlier pipeline asset SHR-1707, which has already progressed to Phase II studies. The approval underscores Hengrui's strategic push into neurodegenerative disease treatments as it diversifies its innovation portfolio beyond oncology and metabolic disorders.